Generic Name and Formulations:
Bimatoprost 0.01%, 0.03%; oph soln; contains benzalkonium chloride.
Indications for LUMIGAN:
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
≥16yrs: 1 drop once daily in the PM.
<16yrs: not recommended.
Do not exceed recommended dose. Renal or hepatic impairment. Ocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Allow at least 5 minutes between application of other topical ophthalmic agents.
Conjunctival hyperemia, eyelash growth, ocular itching or dryness, visual disturbances, foreign body sensation, other local effects, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, blepharitis, cataract, keratitis, photophobia, infection, headache, abnormal liver function tests, asthenia, hirsutism.
Soln—2.5mL, 5mL, 7.5mL
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Comorbid Narcolepsy and Schizophrenia in Adolescents
- FDA Approves New Treatment for Opioid Dependence
- Gestational Diabetes Associated With Increased Risk for Postpartum Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Smartphone-Based Psychoeducational Programs May Be Effective for Bipolar Disorder Management
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Risk Factors for Recurrent Suicide Attempts in Substance Use Disorder Outpatients